Veradermics, Inc

Listed Company

MANECIK 0001827635NYSENon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-70.00M

Total Assets

$152.62M

Equity

$-121.01M

Shares Out

37.34M

Op. Cash Flow

$-71.60M

Business

Veradermics, Inc is a publicly listed company in Pharmaceutical Preparations, incorporated in Delaware. Common stock trades on NYSE under the ticker MANE.

Auto-generated from company profile

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Research and development	62	23
General and administrative	10	3
Total operating expenses	72	27
Loss from operations	−72	−27
Interest income	2	481,000
Other income	790,000	394,000
Interest expense	0	−585,000
Total other income, net	2	290,000
Loss before income taxes	−70	−26
Income tax benefit	0	0
Net loss	−70	−27
Net loss attributable to common stock, basic	−83	−27
Net loss attributable to common stock, diluted	−83	−27
Net loss per share of common stock, basic (in usd per share)	−111.91	−37.05
Net loss per share of common stock, diluted (in usd per share)	−111.91	−37.05
Weighted average common stock outstanding, basic (in shares)	744,991	736,933
Weighted average common stock outstanding, diluted (in shares)	744,991	736,933
Net unrealized gains on marketable securities	60,000	0
Total other comprehensive income	60,000	0
Total comprehensive loss	−70	−26

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Cash and cash equivalents	22	53	—
Marketable securities at fair value	120	0	—
Prepaid expenses and other current assets	11	2	—
Total current assets	152	56	—
Property, plant and equipment, net	22,000	0	—
Right-of-use asset and other long-term assets	100,000	0	—
Total non-current assets	125,000	0	—
Total assets	153	56	—
Accounts payable	2	2	—
Accrued expenses	7	2	—
Other current liabilities and lease liabilities	47,000	0	—
Total current liabilities	9	5	—
Lease liabilities - non-current	4,000	0	—
Total liabilities	9	5	—
Commitments and contingencies (Note 10)	—	—	—
Subscription receivable	−2	−4	−894,000
Common stock, $0.00001 par value, 98,774,582 and 25,500,000 authorized as of December 31, 2024 and 2023, respectively and 7,418,740 shares issued and outstanding	1,000	1,000	—
Additional paid-in capital	2	750,000	—
Accumulated other comprehensive income	60,000	0	—
Accumulated deficit	−123	−49	—
Total stockholders deficit	−121	−48	−22
Total liabilities, redeemable convertible preferred stock, and stockholders deficit	153	56	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Stock-based compensation	1	250,000
Research and development expenses paid with convertible and promissory notes	0	234,000
Non-cash research and development services	2	1
Net accretion of discount/premium on debt securities	−556,000	0
Accrued interest earned	−647,000	0
Other	43,000	573,000
Prepaid expenses and other current assets	−8	−1
Accounts payable	−122,000	646,000
Accrued expenses	5	1
Other current liabilities and lease liabilities	−39,000	0
Net cash used in operating activities	−72	−24
Purchase of property, plant and equipment	−24,000	0
Purchases of marketable securities	−144	0
Maturities of marketable securities	25	0
Net cash used in investing activities	−119	0
Issuance of convertible notes	0	9
Payment of promissory note	0	−845,000
Exercise of stock options	156,000	0
Net cash provided by financing activities	159	60
Net increase (decrease) in cash and cash equivalents	−31	37
Cash paid during the year for interest	0	95,000
Cash paid during the year for income taxes	0	0
Right-of-use asset exchanged for lease liabilities	90,000	0
Unrealized gain on debt securities	60,000	0
Issuance of Series B preferred stock for contractual research and development services	0	3
Issuance of Series B preferred stock as payment for convertible notes	0	10
Issuance of convertible note for research and development services	0	1
Conversion of other receivable in exchange for research and development services to subscription receivable	0	932,000
Issuance of convertible note for accounts payable	0	250,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro